Skip to main content

ANIP

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

ANIP Price
Price Chart

Forward-looking statistics

Beta
0.69
Risk
39.07%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees461
Market cap$1.4B

Fundamentals

Enterprise value$1.8B
Revenue$674.1M
Revenue per employee—
Profit margin-3.12%
Debt to equity142.03

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.18
Dividend per share—
Revenue per share$34.67
Avg trading volume (30 day)$19M
Avg trading volume (10 day)$17M
Put-call ratio—

Macro factor sensitivity

Growth+3.5
Credit+11.5
Liquidity-3.7
Inflation-0.9
Commodities-0.2
Interest Rates-0.2

Valuation

Dividend yield0.00%
PEG Ratio11.80
Price to sales2.10
P/E Ratio11.80
Enterprise Value to Revenue2.68
Price to book3.12

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (May 27, 2025)
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research (May 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free